E Koumantakis

University of Crete, Retimo, Crete, Greece

Are you E Koumantakis?

Claim your profile

Publications (86)145.35 Total impact

  • I Matalliotakis · D Kiriakou · I Fragouli · S Sifakis · G Eliopoulos · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Cytokines released by various cell subsets in the male urogenital tract are capable of markedly influencing sperm function and fertility. Interleukin-6 (IL-6) levels were determined by "sandwich" enzyme immunoassay in the seminal plasma of 77 men divided as follow: (1) into 7 groups according to the etiological diagnosis of fertility, and (2) into 2 groups on the basis of normal or abnormal spermiogram. There was a statistically significant association between IL-6 and the patients' status (P < 0.0014). These results are due to statistically significant differences between the groups with infection of the accessory genital glands and normal controls, as well as between the groups with infection of the accessory genital glands and that with varicocele, indicated by the Honestly Significant Differences (HSD) test for multiple comparisons. There was no significant difference of IL-6 levels between men with normal and those with abnormal spermiograms. Furthermore, there was no correlation between IL-6 levels and the variables of the spermiogram. The prostate seems to be the main site of origin of IL-6 in the seminal plasma. Our data suggest that urogenital infections may lead to elevated levels of IL-6 in the seminal plasma. This measurement of IL-6 in semen may provide clinically useful information for the diagnosis of male accessory gland infection.
    Archives of Andrology 07/2009; 41(1):43-50. · 0.89 Impact Factor
  • I. Matalliotakis · M. Neonaki · P. Prokopakis · E. Koumantakis ·

    Journal of Obstetrics and Gynaecology 07/2009; 14(2). DOI:10.3109/01443619409030025 · 0.55 Impact Factor
  • S Sifakis · O Koukoura · N Mantas · V Velissariou · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We report a case of trisomy 21 mosaicism detected upon amniocentesis in a 36-year-old woman. Ultrasound examination at 23 weeks' gestation showed a fetus with hydrops, pulmonary hypoplasia, oligohydramnios, thickened placenta, and intrauterine growth retardation. Cytogenetic analysis revealed low-percentage (6%) mosaicism for trisomy 21. Hydrops fetalis and thickened placenta are uncommon findings in fetuses affected by trisomy 21 mosaicism. A short review of the literature is given regarding the sonographic findings associated with trisomy 21 mosaicism, and the genetic counseling in such cases.
    Fetal Diagnosis and Therapy 11/2008; 24(3):310-2. DOI:10.1159/000160218 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the concentrations of human placental growth hormone (hPGH) in amniotic fluid (AF) at gestational mid-trimester in normal pregnancies and in pregnancies complicated by Down's syndrome. AF samples from 21 women with Down's syndrome pregnancies were analyzed retrospectively. About 47 AF samples from women with singleton, uncomplicated pregnancies, who gave birth to healthy neonates with birth weight appropriate for gestational age were used as controls. All AF samples were obtained during amniocentesis for fetal karyotyping at 16-23 weeks' gestation. hPGH levels were measured by a solid phase immunoradiometric assay using two different epitopes. The mean hPGH values in the AF of the Down's syndrome-affected pregnancies were significantly higher (P<0.05) compared to those of normal pregnancies, at 16-23 weeks' gestation: mean-value+/-SD in the AF was 1.96+/-1.35 microg/l vs. 0.82+/-0.67 microg/l. Higher hPGH levels in AF were found in pregnancies affected by Down's syndrome as compared to normal pregnancies at gestational mid-trimester. hPGH was detected in all AF samples, and it provides evidence that this pregnancy-specific hormone enters the fetal compartment and is not limited to the maternal circulation. The physiological role and effect of hPGH on fetal growth in normal and pathological pregnancies needs further investigation.
    Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 10/2008; 19(2):121-5. DOI:10.1016/j.ghir.2008.08.002 · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amniotic band syndrome is an uncommon, congenital fetal abnormality with multiple disfiguring and disabling manifestations. A wide spectrum of clinical deformities are encountered and range from simple ring constrictions to major craniofacial and visceral defects. We report a case of constriction amniotic bands involving upper extremities and intrauterine fetal death due to strangulation of umbilical cord. Abnormally elevated levels of alpha-fetoprotein and beta-chorionic gonadotropin were detected at 17 weeks' gestation. They were probably caused by the loss of cutaneous integrity of the fetus (alpha-fetoprotein), and by the placental attempt to counteract the fetal growth restriction and hypoxia, due to the strangulation of umbilical cord by the amniotic bands (beta-chorionic gonadotropin).
    Fetal Diagnosis and Therapy 07/2008; 24(2):111-4. DOI:10.1159/000142139 · 2.94 Impact Factor
  • Source

    Ultrasound in Obstetrics and Gynecology 10/2007; 30(4):649 - 649. DOI:10.1002/uog.5066 · 3.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this randomized study was to compare the effectiveness, safety, and side effects of 6 h vaginal misoprostol versus vaginal prostaglandin E(2) (PGE(2)) for labor induction. Fifty microgram of misoprostol was given intravaginally in the misoprostol group (204 women), and 3 mg PGE(2) was given intravaginally in the PGE(2) group (211 women). In both groups, the dose was repeated every 6 h for a maximum of three doses, until active labor was achieved. Artificial rupture of membranes and oxytocin infusion was used during labor in both groups where it was indicated. The mean interval from the institution of labor induction to delivery was 11.3 +/- 8.6 h for the misoprostol group, and 15.7 +/- 9.3 h for PGE(2 )group (P < 0.05). In the misoprostol group, oxytocin was used less frequently, but there was a higher prevalence of tachysystole. No statistically significant differences were observed between the two groups as regard abnormal patterns of fetal heart rate, the mode of delivery, and the need for neonatal intervention. In conclusion, the intravaginal administration of 50 mug misoprostol at 6 h interval (maximum three doses) is comparable in safety, but more effective for induction of labor than 3 mg intravaginal PGE(2).
    Archives of Gynecology and Obstetrics 04/2007; 275(4):263-7. DOI:10.1007/s00404-006-0258-4 · 1.36 Impact Factor
  • N Mantas · Stavros Sifakis · O Koukoura · E Avgoustinakis · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Dilatation of the fetal umbilical vein is a rare, most commonly isolated finding. Approximately 100 cases have been reported in the literature that describe different management approaches, especially regarding the time of delivery. We present a new case of umbilical vein dilatation diagnosed at 23 weeks' gestation as an isolated sonographic finding, in a fetus with short umbilical cord, delivered at 38 weeks' gestation. The clinical and sonographic features as well as the management options of this uncommon condition are shortly discussed.
    Fetal Diagnosis and Therapy 02/2007; 22(6):431-4. DOI:10.1159/000106349 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the relationship between maternal serum and amniotic fluid levels of human Placental Growth Hormone (hPGH) with the fetal intrauterine growth retardation (IUGR) related to preeclampsia. We analyzed samples in pairs of serum and amniotic fluid retrospectively from 25 women, who manifested preeclampsia and IUGR in the late second or the third trimester of gestation. The samples were obtained at 16-22 weeks' gestation during amniocentesis for fetal karyotyping. At this time, there was no clinical or sonographic evidence of preeclampsia or IUGR, respectively. Sixty-two serum samples were used as controls which were obtained at 16-22 weeks' gestation from women with singleton, uncomplicated pregnancies, with normal outcome, and appropriate for gestational age neonatal birth weight. Forty-seven amniotic fluid samples were also used as controls which were obtained at 16-22 weeks' gestation from the women that were included in the control group who underwent an amniocentesis. hPGH levels were measured by a solid phase immunoradiometric assay. The mean hPGH values in the serum and the amniotic fluid of the IUGR related to preeclampsia affected pregnancies were significantly higher (P<0.05) than those of the normal pregnancies at 16-22 weeks' gestation: mean+/-SD in the serum was 13.16+/-10.52 ng/ml vs. 4.39+/-2.23 ng/ml; mean+/-SD in the amniotic fluid 2.49+/-1.6 ng/ml vs. 0.82+/-0.67 ng/ml. hPGH levels in maternal serum and amniotic fluid were found to be higher at 16-22 weeks' gestation in pregnancies that will be complicated subsequently by IUGR related to preeclampsia. Our findings suggest that the evaluation of the changes of hPGH levels at midtrimester should be further investigated for the possibility to provide a potential predictive index of IUGR and preeclampsia.
    Growth Hormone & IGF Research 10/2006; 16(5-6):290-6. DOI:10.1016/j.ghir.2006.06.006 · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypochondroplasia (HCH) is an autosomal dominant skeletal dysplasia characterized by short extremities, short stature and lumbar lordosis, usually exhibiting a phenotype similar to but milder than achondroplasia (ACH). Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are present in a significant proportion of HCH patients. Reports of prenatal diagnosis of HCH are very rare and the phenotype/genotype correlation in these patients is poor. Here we present two sporadic cases with second trimester ultrasound findings consistent with a diagnosis of a non-lethal skeletal dysplasia. Ultrasound evaluation after 23 weeks of gestation showed a decreased rate of development of the femora (femur length <fifth centile), while biparietal diameter, abdominal circumference, and foot length were within normal limits. Femur length/foot and femur length/abdominal circumference ratios were <0.87 and <0.18, respectively. Prenatal cytogenetic and molecular genetic analysis was performed. Karyotype was normal and FGFR3 G380R mutation characteristic of ACH was excluded in both fetuses. Molecular genetic analysis carried out retrospectively revealed that both fetuses were heterozygous for the C1620A mutation resulting in N540K substitution in FGFR3, the most common mutation in HCH. We conclude that the combination of ultrasound and molecular genetic approach is helpful for establishing an accurate diagnosis of HCH in utero and subsequently for appropriate genetic counseling and perinatal management.
    American Journal of Medical Genetics Part A 05/2006; 140(9):998-1003. DOI:10.1002/ajmg.a.31177 · 2.16 Impact Factor
  • O Koukoura · S Sifakis · G Stratoudakis · N Mantas · P Kaminopetros · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Anencephaly is a rare congenital anomaly in which the forebrain, meninges, vault of the skull, and scalp all fail to form. We report a case of a 32-year-old gravida 2 woman with an anencephalic fetus detected at the 21st gestational week. She had a history of an intrauterine fetal death of an anencephalic fetus at the 20th gestational week two years before. We present the case and briefly review the literature.
    Clinical and experimental obstetrics & gynecology 02/2006; 33(3):185-9. · 0.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta1 (TGF-beta1), endothelin-1 (ET-1) and soluble c-kit ligand (sKL) are cytokines involved in embryogenesis. Maternal plasma cytokines were measured with ELISA during the three trimesters of gestation and on the day of delivery in 93 pregnant women and 18 age-matched non-pregnant control women. The VEGF and bFGF levels increased during the first trimester and declined thereafter, but they remained above the controls' values until delivery. The TGF-beta1 levels increased during the first trimester and remained unchanged thereafter. On the contrary, the ET-1 levels decreased and remained low until delivery. VEGF, bFGF, TGF-beta1 and ET-1 were increased in hypertensive pregnancy. Except for ET-1, these cytokines were also increased in gestational diabetes. No changes in plasma sKL were documented. All the aforementioned cytokines play a role in uncomplicated pregnancy, whereas hypertensive pregnancy is causatively-related with increased ET-1.
    In vivo (Athens, Greece) 01/2006; 20(1):157-63. · 0.97 Impact Factor
  • NA Kailas · S Sifakis · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Perimenopause marks the transition from normal ovulation to anovulation and ultimately to permanent loss of ovarian function. Fecundity, the average monthly probability of conception, declines by half as early as the mid-forties, however women during the perimenopause still need effective contraception. Issues arising at this period such as menstrual cycle abnormalities, vasomotor instability, the need for osteoporosis and cardiovascular disease prevention, as well as the increased risk of gynecological cancer, should be taken into consideration before the initiation of a specific method of contraception. Various contraceptive options may be offered to perimenopausal women, including oral contraceptives, tubal ligation, intrauterine devices, barrier methods, hormonal injectables and implants. Recently, new methods of contraception have been introduced presenting high efficacy rates and minor side-effects, such as the monthly injectable system, the contraceptive vaginal ring and the transdermal contraceptive system. However, these new methods have to be further tested in perimenopausal women, and more definite data are required to confirm their advantages as effective contraceptive alternatives in this specific age group. The use of the various contraceptive methods during perimenopause holds special benefits and risks that should be carefully balanced, after a thorough consultation and according to each woman's contraceptive needs.
    The European Journal of Contraception and Reproductive Health Care 04/2005; 10(1):19-25. DOI:10.1080/13625180400020861 · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy. One hundred and thirty anemic pregnant women were studied. Inclusion criteria were iron-deficiency type of anemia, and hemoglobin levels below of 11.5, 10.9 and 10.3 g/dl for the three trimesters of pregnancy, respectively. Twenty-five women who presented pregnancy-related complications were excluded during treatment. The remaining 105 were treated with 1600-mg iron protein succinylate per os daily for a period of four months. A group of anemia-related clinical signs and symptoms, and hematological parameters were recorded at the beginning of treatment, as well as two and four months later. They included epidermis and mucosal paleness, skin and nail lesions, glossitis, heart pulse, sickness, anorexia, apathy, ataxia, polypnea, insomnia, nervousness, paresthesias and other neurological symptoms; the hematological parameters included Hgb, hct, RBCs, WBCs, MCV, MCH, MCHC, PLTs, serum Fe and ferritin. Possible side or adverse effects were considered during treatment. The majority of symptoms and signs of anemia were gradually improved. There was a statistically significant increase in the means of Hgb, hct, WBCs, MCV, MCH, PLTs and serum ferritin (p < 0.05). Anemia was effectively treated in 100/105 (95.2%) women, but not in five patients (4.8%) who displayed poor compliance to the therapeutic protocol. There were transient and mild side-effects in seven (6.6%) treated women, namely diarrhea, epigastralgia, vomiting, and nausea, which however, did not necessitate discontinuation of the therapeutic protocol. Iron protein succinylate is an effective and well tolerated treatment of iron-deficiency anemia in pregnancy.
    Clinical and experimental obstetrics & gynecology 01/2005; 32(2):117-22. · 0.42 Impact Factor
  • S Sifakis · I G Panayiotides · E Angelakis · N Martavatzis · E Koumantakis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Struma ovarii is a type of mature ovarian teratoma consisting mainly of thyroid tissue. The rarity of this tumor in pregnancy and the risk of malignancy make difficult the diagnosis and the management. CASE REPORT: We report a case of benign struma ovarii initially detected as an ovarian mass at the first trimester of pregnancy.
    Archives of Gynecology and Obstetrics 12/2003; 269(1):72-3. DOI:10.1007/s00404-003-0536-3 · 1.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study reports about the effect of doxycycline and/or metronidazole on colonization by Candida organisms of the human gastrointestinal (GI), oropharyngeal tract and vagina. Treatment with doxycycline or metronidazole for 10 days increased, but not significantly, the GI, oropharyngeal or vaginal colonization by Candida species. The combination of doxycycline and metronidazole, used for the same period, caused a significant increase of 2.5 log10 CFU/g of stools (mean) colonization by Candida. Likewise, 2 out of 9 patients treated with the combination had substantially increased colonization of their vagina by Candida species. This effect, however, could not be expressed statistically due to the semiquantitative nature of the vaginal cultures. In contrast, the combination did not increase oropharyngeal colonization. In conclusion, doxycycline and metronidazole as monotherapies, did not increase significantly Candida colonization in the cavities examined. The combination of doxycycline and metronidazole had a substantial effect, increasing the GI and vaginal colonization by Candida organisms.
    Journal of chemotherapy (Florence, Italy) 09/2003; 15(4):369-73. DOI:10.1179/joc.2003.15.4.369 · 1.60 Impact Factor
  • Source
    M. Rasidaki · A. T. Papageorghiou · E. Vardaki · S. Sifakis · E. Koumantakis ·

    Ultrasound in Obstetrics and Gynecology 01/2003; 22(S1):118 - 118. DOI:10.1002/uog.643 · 3.85 Impact Factor
  • E Karteris · A Goumenou · E Koumantakis · E W Hillhouse · D K Grammatopoulos ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Placentally derived CRH seems to play a major role in the mechanisms controlling human pregnancy and parturition, via activation of specific receptors widespread in reproductive tissues. In the human placenta, CRH seems to modulate vasodilation, prostaglandin production, and ACTH secretion. It has also been suggested that CRH might act as a placental clock, determining the length of gestation. In addition, maternal plasma CRH concentrations are further elevated in pregnancies associated with abnormal placental function, such as preeclampsia and intrauterine growth retardation (IUGR). In this study, we sought to investigate the expression of CRH-R1 alpha levels in placentas from women who have undergone normal deliveries (control group) and patients who have been diagnosed as having preeclampsia or IUGR. Results showed that placental CRH-R1 alpha mRNA levels (as shown by quantitative RT-PCR) and protein levels (shown by Western blotting analysis) were significantly (P < 0.05) reduced in all of the complicated pregnancies. In contrast, levels of the angiotensin II receptor were elevated in preeclampsia and reduced in IUGR subjects, as shown by RT-PCR and Western blotting analysis. These findings might suggest that changes in receptor expression may contribute toward dysregulation of the dynamic balance controlling vascular resistance.
    Journal of Clinical Endocrinology &amp Metabolism 01/2003; 88(1):363-70. DOI:10.1210/jc.2002-020375 · 6.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the Bcl-2 and Bax expressions in endometriotic and adenomyotic tissues. In addition, to evaluate the Bcl-2/Bax status during the menstrual cycle in these tissues. A total of 56 women were retrospectively recruited from a University hospital setting. A total of 25 had endometriosis and 31 adenomyosis. Tissue samples were collected during gynaecological surgery and confirmed by histology to have endometriosis or adenomyosis. Bcl-2 and Bax expressions were investigated on 56 formalin-fixed and paraffin-embedded tissue by immunohistochemical staining and electron microscopy. The difference of Bcl-2-positive protein between endometriosis and adenomyosis was not significant. No significant difference was found between Bcl-2 expression and the proliferative and secretory phase of the cycle in women with endometriosis, but this comparison was highly significant (P<0.001) in women with adenomyosis. The difference of Bax-positive protein between endometriosis and adenomyosis was not significant. In addition, no significant differences were found between the various phases of the cycle. We have found a stronger inverse correlation between the expression of Bcl-2 and Bax in endometriosis than in adenomyosis. Our results suggest that the pathogenesis of ovarian endometriosis may be different from that of adenomyosis and the persistence of Bcl-2 and Bax expressions during both phases of the cycle in ovarian endometriotic tissues may have important implications for the survival and proliferation of the ectopic endometrial tissue.
    European Journal of Obstetrics & Gynecology and Reproductive Biology 12/2001; 99(2):256-60. DOI:10.1016/S0301-2115(01)00381-5 · 1.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the concentration of plasma carnitine (total, free, and acylcarnitine) during the delivery of uncomplicated pregnancies of adolescent women. To investigate the relationship between maternal and neonatal levels of carnitine and to compare these carnitine levels between pregnant and nonpregnant adolescents. Samples of maternal and umbilical blood were taken at the time of delivery and examined for the determination of the carnitine-total, free, and acylcarnitine-concentration by the use of an enzymatic-radioisotope method. Twenty-two cases of uncomplicated adolescent pregnancies with a normal labor and without perinatal complications were examined. The plasma level of carnitine was also examined in 17 healthy nonpregnant adolescent women, which constituted the control group. The concentrations of plasma carnitine in adolescent pregnancies at the time of delivery were calculated at 19.6 +/- 2.15 microMol/L (total), 12.62 +/- 1.31 microMol/L (free), and 6.98 +/- 1.55 microMol/L (acylcarnitine). The corresponding mean values in umbilical plasma were 30.31 +/- 2.06 microMol/L, 22.39 +/- 1.64 microMol/L, and 7.92 +/-.96 mucroMol/L. There is a statistically significant difference between the mean values in maternal and umbilical plasma (P <.0001 for total and free carnitine and P <.012 for acylcarnitine). The correlations between adolescent pregnant women and their infants as regards total, free, and acylcarnitine were 0.137, 0.018, and 0.33, respectively. Neither of these parameters was statistically significant. The corresponding mean values of carnitine in nonpregnant adolescent women were statistically significantly higher than in adolescent pregnant women (total carnitine: 41.61 +/- 3.09 microMol/L, free: 31.39 +/- 2.81 microMol/L, acylcarnitine: 10.22 +/- 1.88 microMol/L, P <.0001). The concentration of plasma carnitine at the end of adolescent pregnancy is low compared to the levels of umbilical carnitine at birth and that found in nonpregnant adolescent women. It may not have an obvious impact on the utilization of fatty acids in an uncomplicated full-term pregnancy; however, it suggests the potential risk for neonatal fatty-acid oxidation in a preterm or complicated pregnancy.
    Journal of Pediatric and Adolescent Gynecology 05/2001; 14(2):65-9. DOI:10.1016/S1083-3188(00)00089-9 · 1.68 Impact Factor

Publication Stats

1k Citations
145.35 Total Impact Points


  • 1997-2009
    • University of Crete
      • • Department of Obstetrics and Gynaeocology
      • • School of Medicine
      • • Department of Radiotherapy
      Retimo, Crete, Greece
  • 1996-2008
    • University Hospital of Heraklion
      • Department of Gastroenterology
      Irákleio, Attica, Greece
  • 2001
    • A. Sygros Hospital
      Athínai, Attica, Greece
  • 1999
    • Alexandra Regional General Hospital
      Athínai, Attica, Greece
  • 1997-1998
    • University General Hospital
      Houston, Texas, United States
  • 1995
    • National Hellenic Research Foundation
      Athínai, Attica, Greece